SSH Communications Security Corporation
SSH Communications Security Oyj - Managers' Transactions
SSH Communications Security Plc has today received the following notification:
Person subject to the notification requirement
Name: Tunkelo, Teemu
Position: Chief Executive Officer
Issuer: SSH Communications Security Oyj
LEI: 7437007N96FK4N3WHT09
Notification type: INITIAL NOTIFICATION
Reference number: 7437007N96FK4N3WHT09_20210224142451_4
____________________________________________
Transaction date: 2021-02-22
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009008270
Nature of the transaction: ACQUISITION
Transaction details
(1): Volume: 52 Unit price: 2.41 EUR
(2): Volume: 848 Unit price: 2.42 EUR
Aggregated transactions
(2): Volume: 900 Volume weighted average price: 2.41942 EUR
____________________________________________
Transaction date: 2021-02-24
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009008270
Nature of the transaction: ACQUISITION
Transaction details
(1): Volume: 602 Unit price: 2.64 EUR
(2): Volume: 1,398 Unit price: 2.65 EUR
Aggregated transactions
(2): Volume: 2,000 Volume weighted average price: 2.64699 EUR
For further information, please contact:
Niklas Nordström, CFO, tel. +358 50 541 0543
Markku Karppi, General Counsel, tel. + 358 50 586 0552
Distribution:
Nasdaq Helsinki Ltd.
Major media
www.ssh.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novo Nordisk A/S8.11.2025 09:18:56 CET | Press release
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
Teva Pharmaceutical Industries Ltd8.11.2025 00:00:00 CET | Press release
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
Columbus A/S7.11.2025 23:46:30 CET | Press release
Notification of transactions in Columbus A/S shares and related securities by persons discharging managerial responsibilities and persons closely associated with them
Evaxion7.11.2025 23:10:00 CET | Press release
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
VALLOUREC7.11.2025 18:45:00 CET | Press release
VALLOUREC ANNOUNCES A TRANSITION IN ITS FINANCIAL MANAGEMENT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
